RED-HF trial was started in year 2006 and results reported in jan-2013. RED-HF trial included 2278 patients with anemia and left ventricular systolic dysfunction. These patients were randomized to Darbepoetin Alfa or placebo, the main aim of treatment group was to achieve HB% of 13grm/dl. Primary end point was composite death due to any cause or worsening of heart failure and readmission. There was no benfit by Darbepoetin alpha versus placebo (hazard ratio 1.01, 95% CI 0.90-1.13).
Stroke and Darbepoetin
Darbepoetin increases the risk of stroke without clinical benfit. Still FDA has approved usage of Darbepoetin in chronic kidney disease with anemia